(Q73874722)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10844903%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

review article

1 reference

title

Herpes simplex type 2 infections--an update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10844903%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10844903%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

S E Straus

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10844903%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 May 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10844903%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10844903%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10844903%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10844903%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

325-359

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10844903%20AND%20SRC:MED&resulttype=core&format=json

Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Molecular phylogeny of the alphaherpesvirinae subfamily and a proposed evolutionary timescale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparan sulphate and glycoprotein B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

An HSV LAT null mutant reactivates slowly from latent infection and makes small plaques on CV-1 monolayers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Correlation between herpes simplex virus type 1 rate of reactivation from latent infection and the number of infected neurons in trigeminal ganglia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Evidence that deficient IFN-gamma production is a biological basis of herpes simplex virus type-2 neurovirulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Effect of antibody alone and combined with acyclovir on neonatal herpes simplex virus infection in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Passive immunization with monoclonal antibodies against herpes simplex virus glycoproteins protects mice against herpetic ocular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8-positive cytolytic T lymphocyte response to herpes simplex virus in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Pathogenesis of Herpes Simplex Virus in Congenitally Athymic Mice: the Relative Roles of Cell-mediated and Humoral Immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

A viral inhibitor of peptide transporters for antigen presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Herpes simplex virus turns off the TAP to evade host immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Herpes simplex virus type 2 in the United States, 1976 to 1994.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Risk Factors for the Sexual Transmission of Genital Herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Frequency of asymptomatic shedding of herpes simplex virus in women with genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

The Association Between Genital Ulcer Disease and Acquisition of HIV Infection in Homosexual Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Herpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human T lymphotropic virus type I infections. The Johns Hopkins University (JHU)/Centre pour le Developpem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Association between human immunodeficiency virus and herpes simplex virus type 2 seropositivity among male factory workers in Zimbabwe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Understanding the pathogenesis of HSV-associated erythema multiforme.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Recurrent erythema multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

The acquisition of herpes simplex virus during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Treatment of viral infections during pregnancy and the neonatal period.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis S

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Double-blind Placebo-Controlled Trial of Oral Acyclovir in First-Episode Genital Herpes Simplex Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Current status and prospects for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Intravenous acyclovir therapy of first episodes of genital herpes: a multicenter double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Cost-effectiveness of acyclovir suppression to prevent recurrent genital herpes in term pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Foscarnet-resistant herpes simplex virus infection in patients with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Predicting and preventing the emergence of antiviral drug resistance in HSV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Historical aspects of herpes simplex infections. Part 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Experimental human reinfection with herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Follow-up report on 50 subjects vaccinated against herpes genitalis with Skinner vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

7 January 2021

Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

7 January 2021

Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

7 January 2021

Recovery from lethal herpes simplex virus type 1 infection is mediated by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

7 January 2021

Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models.

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

7 January 2021

The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

7 January 2021

Presentation of neonatal herpes simplex virus infections: implications for a change in therapeutic strategy.

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

7 January 2021

Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

7 January 2021

Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

7 January 2021

DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector

1 reference

https://api.crossref.org/works/10.1016%2FS0011-5029%2800%2990012-9

7 January 2021

10.1016/S0011-5029(00)90012-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10844903%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference